As of 2017, an approximate population of 14 million people in the US were diagnosed with Age-related Macular Degeneration (AMD) [1], with an estimated total of 196 million people being affected worldwide by 2020, increasing to 288 million people by 2040 [2]. Additional studies have shown that there is a strong possibility that AMD is underdiagnosed by up to 25% in primary care, with these cases often being in the very early stage of AMD [3].

However, due to the aggressive nature of Wet AMD, cases are diagnosed more rapidly. Wet AMD also represents approximately 10% of all cases of AMD [4]. This amounts to a total of 1.4 million people in the US as of 2017, with an estimated increase to 2 million people in the US by 2020. Globally Wet AMD will affect an estimated 19.6 million people by 2020 with a projected growth to 28.8 million people by 2040.